TTP LabTech Expands its Custom Automation Business
News May 22, 2007
TTP LabTech has announced further expansion of its Custom Automation business. This follows six years of continuous growth (annual turnover has grown over 24% a year compound) and a doubling of staff numbers to enable delivery of innovative engineering to a broad spectrum of high profile clients.
With unrivalled expertise covering engineering, software, chemistry, and cell biology, TTP LabTech boast a team of exceptional calibre and is set to broaden its global customer base.
With 20 years’ experience developing technologies, TTP LabTech’s custom automation business provides practical and innovative integrated automation across a number of industry sectors.
Recent projects include: automating a chemical synthesis process for increased production efficiency (the Automated Synthesis Laboratory); the development of a tablet coating system with a capacity of 250,000 tablets an hour; the design and integration of instrumentation for High Throughput Formulation Screening (HTFS), to automate specific tasks such as weighing, mixing, heating, filtering or sampling, and the co-development of a revolutionary self-test glucose meter.
Matthew Cook was recently appointed Commercial Development Manager to further develop the custom automation business and address the increasing need for outsourcing across numerous industry sectors, “We have always worked very closely with scientists and engineers to bring fresh technical approaches to the market place, as evidenced by our strong product portfolio. We also manufacture our own products, so understand the need to develop systems that are simple to produce but robust in the field. Our multidisciplinary and highly skilled development teams, and dedicated manufacturing and support groups ensure the delivery of robust, reliable systems, irrespective of size or complexity.”
He continued, “This background has allowed us to apply our expertise across many new industry sectors, to find new and exciting solutions to meet challenging commercial demands.”
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019